FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
 and Lead Plaintiff Deadline - January 3, 2017 - EconoTimes)
NEW YORK, Nov. 10, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed against Allergan PLC (“Allergan” or the “Company”) (NYSE:AGN) and/or Actavis plc and certain of its officers. This class action is on behalf of a class consisting of all persons who purchased Allergan between February 25, 2014 and November 3, 2016, both dates inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Both Allergan and Actavis were involved in and/or had been involved in conduct that would result in an antitrust investigation by the U.S. Department of Justice; (2) the DOJ investigation and the misconduct may instigate U.S. prosecutors to file criminal charges against Allergan and Actavis for alleged price manipulation; (3) as a result, Allergan and Actavis lacked effective internal controls; and (4) consequently, public statements by Allergan and Actavis were materially false and misleading at all relevant times.
No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/agn or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Allergan, you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
